Pfizer News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

29.02.24	Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth (Businesswire)
29.02.24	Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults (Businesswire)
26.02.24	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
19.02.24	European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis (Businesswire)
15.02.24	Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day (Businesswire)
05.02.24	Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities (Businesswire)
30.01.24	Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance (Businesswire)
26.01.24	European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer (Businesswire)
10.01.24	Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation (Businesswire)
09.01.24	TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer (Businesswire)
08.01.24	European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer (Businesswire)
02.01.24	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
19.12.23	Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts (Businesswire)
15.12.23	PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer (Businesswire)
14.12.23	Pfizer Declares First-Quarter 2024 Dividend (Businesswire)
14.12.23	Pfizer Completes Acquisition of Seagen (Businesswire)
13.12.23	Pfizer Provides Full-Year 2024 Guidance (Businesswire)
12.12.23	Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen (Businesswire)
10.12.23	Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B (Businesswire)
08.12.23	European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma (Businesswire)
01.12.23	Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity (Businesswire)
21.11.23	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
02.11.23	Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting (Businesswire)
02.11.23	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
31.10.23	Pfizer Reports Third-Quarter 2023 Results (Businesswire)
26.10.23	Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19 (Businesswire)
20.10.23	FDA Approves PENBRAYA™, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents (Businesswire)
13.10.23	Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance (Businesswire)
12.10.23	U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer (Businesswire)
05.10.23	Pfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious Diseases (Businesswire)
04.10.23	Pfizer Declares Fourth-Quarter 2023 Dividend (Businesswire)
22.09.23	Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV (Businesswire)
19.09.23	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
19.09.23	European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata (Businesswire)
18.09.23	Pfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analysts (Businesswire)
12.09.23	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
11.09.23	Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine (Businesswire)
05.09.23	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
30.08.23	Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences (Businesswire)
30.08.23	Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union (Businesswire)
24.08.23	European Commission Approves Pfizer’s ABRYSVO™ to Help Protect Infants through Maternal Immunization and Older Adults from RSV (Businesswire)
21.08.23	U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age (Businesswire)
14.08.23	Pfizer’s ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma (Businesswire)
01.08.23	Pfizer Reports Second-Quarter 2023 Results (Businesswire)
27.07.23	Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy (Businesswire)
21.07.23	Pfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility (Businesswire)
19.07.23	Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate (Businesswire)
28.06.23	FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency (Businesswire)
27.06.23	FDA Accepts Pfizer’s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec (Businesswire)
26.06.23	Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Logitech Intl	74.04	2.41 %	K V
ABB	52.12	1.68 %	K V
Geberit	552.80	1.32 %	K V
Alcon	78.04	1.19 %	K V
CieFinRichemont	129.05	1.10 %	K V
Swiss Life Hldg	686.00	-0.64 %	K V
Zurich Insur Gr	555.20	-1.00 %	K V
Holcim	90.66	-1.31 %	K V
Kuehne+Nagel Int	210.60	-1.31 %	K V
Novartis	90.10	-3.14 %	K V

Nachrichten zu Pfizer Inc Cert.Deposito Arg.Repr. 0.5 Shs

Aktien Top/Flop

Pfizer Peer Group Nachrichten

Meistgelesene Nachrichten